Triple
T17871418
| Position | Surface form | Disambiguated ID | Type / Status |
|---|---|---|---|
| Subject | Alnylam Pharmaceuticals, Inc. |
E446844
|
entity |
| Predicate | develops |
P73
|
FINISHED |
| Object | AMVUTTRA (vutrisiran) |
—
|
NE NERFINISHED |
How this triple was built (3 steps)
Every LLM step that produced this triple, in pipeline order — named-entity classification, the disambiguation choices (the exact options shown, with the pick highlighted), and the generated description. The batch + timestamp of each is in the Provenance table below.
NER
Named-entity recognition
gpt-5-mini
Instruction
Given a phrase, classify it is english named entity (e.g., persons, organizations, works of art) in Latin script, or not (e.g., literals, dates, URLs, verbose phrases). For disambiguation, the statement where the phrase occurs as object is also given. Please return a JSON object with `phrase` (string, the phrase being analyzed) and `is_ne` (boolean, indicating whether the phrase is a Named Entity).
Input
Phrase: AMVUTTRA (vutrisiran) | Statement: [Alnylam Pharmaceuticals, Inc., develops, AMVUTTRA (vutrisiran)]
NED1
Entity disambiguation (via context triple)
gpt-5-mini-2025-08-07
Target entity: AMVUTTRA (vutrisiran) Context triple: [Alnylam Pharmaceuticals, Inc., develops, AMVUTTRA (vutrisiran)]
-
A.
Evrysdi
Evrysdi is an oral prescription medication used to treat spinal muscular atrophy (SMA) by increasing production of the survival motor neuron (SMN) protein.
-
B.
Vitrakvi
Vitrakvi is a targeted cancer therapy (larotrectinib) used to treat solid tumors that have a specific NTRK gene fusion, regardless of the tumor’s location in the body.
-
C.
inotersen
Inotersen is an antisense oligonucleotide drug used to treat hereditary transthyretin-mediated amyloidosis by reducing the production of transthyretin protein.
-
D.
Spinraza
Spinraza is a prescription medication used to treat spinal muscular atrophy (SMA) by modifying SMN2 gene expression to increase production of survival motor neuron (SMN) protein.
-
E.
AveXis
AveXis is a biotechnology company best known for developing the gene therapy onasemnogene abeparvovec (Zolgensma) for spinal muscular atrophy.
- F. None of above. chosen
- G. Unsure - the case is ambiguous/there is not enough information to decide.
NED2
Entity disambiguation (via description)
gpt-5-mini-2025-08-07
Target entity: AMVUTTRA (vutrisiran) Target entity description: AMVUTTRA (vutrisiran) is an RNA interference (RNAi) therapeutic used to treat hereditary transthyretin-mediated (hATTR) amyloidosis by reducing the production of transthyretin protein.
-
A.
Evrysdi
Evrysdi is an oral prescription medication used to treat spinal muscular atrophy (SMA) by increasing production of the survival motor neuron (SMN) protein.
-
B.
Vitrakvi
Vitrakvi is a targeted cancer therapy (larotrectinib) used to treat solid tumors that have a specific NTRK gene fusion, regardless of the tumor’s location in the body.
-
C.
inotersen
Inotersen is an antisense oligonucleotide drug used to treat hereditary transthyretin-mediated amyloidosis by reducing the production of transthyretin protein.
-
D.
Spinraza
Spinraza is a prescription medication used to treat spinal muscular atrophy (SMA) by modifying SMN2 gene expression to increase production of survival motor neuron (SMN) protein.
-
E.
AveXis
AveXis is a biotechnology company best known for developing the gene therapy onasemnogene abeparvovec (Zolgensma) for spinal muscular atrophy.
- F. None of above. chosen
Provenance (2 batches)
The batch behind each pipeline step, in order, with when it ran. Timestamps are batch-level — stages were processed in waves, so the object chain (NER → NED1 → NEDg → NED2) reads in order, but predicate / elicitation batches can sit in a different wave.
| Step | Stage | Batch ID | Status | When |
|---|---|---|---|---|
| creating | Elicitation | batch_69d8b9f4c22c819093c2680434472894 |
completed | April 10, 2026, 8:51 a.m. |
| NER | Named-entity recognition | batch_69e49aa30ff8819090c51c1d7767e952 |
completed | April 19, 2026, 9:04 a.m. |
Created at: April 10, 2026, 10:18 a.m.